

PRESS RELEASE

08 November 2023 15:45:00 CET

Senzime publishes prospectus relating to the directed share issue

Senzime AB (publ) ("Senzime" or "the Company") announced on 25 September 2023 that the Board of Directors had resolved on a directed issue of shares of approximately SEK 117 million (the "Share Issue"). The Board of Directors' resolution of the Share Issue was approved by the Extraordinary General Meeting on 19 October 2023.

The prospectus regarding the admission to trading of the new shares on Nasdaq Stockholm has today on 8 November 2023 been approved and registered by the Swedish Financial Supervisory Authority, and is available in Swedish on Senzime's website, www.senzime.com as well as on the Swedish Financial Supervisory Authority's website, www.fi.se.

Advisers

In connection with the Share Issue, the Company has retained Zonda Partners as financial advisor and Advokatfirman Lindahl KB as legal adviser to the Company.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction.

This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from the Company nor from someone else. No action has been taken, and no action will be taken, to allow a public offering in any jurisdiction other than Sweden. An invitation to eligible persons to subscribe for shares in the Company has only been made through the prospectus that the Company published today, 8 November 2023.

The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States of America, including its territories and possessions, any state of the United States and the District of Columbia (the "**United States**"), Australia, Canada, Hong Kong, Japan, New Zealand, Switzerland, Singapore, South Africa or South Korea or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the "**Securities Act**"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

Within the European Economic Area ("**EEA**"), no public offering is intended to be made in any member state other than Sweden. In other member states of the EEA where the Prospectus Regulation applies, an offer of securities may only be made in accordance with exemptions in the Prospectus Regulation and any implementing measures. In the United Kingdom, an offering of securities may only be made to qualified investors in accordance with exemptions in the Prospectus Regulation and applicable law in the United Kingdom. Persons in any member state of the EEA other than Sweden or in the United Kingdom who are not qualified investors under applicable law should not take any action based on this press release, nor should they rely on it.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. The Company has prepared and today published a prospectus for the Share Issue. The Prospectus has been reviewed and approved by the Swedish Financial Supervisory Authority (SWE: Finansinspektionen) being the national competent authority and is available on the Company's website. This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. Any investment decision should, in order for an investor to fully understand the potential risks and benefits associated with the decision to participate in the Share Issue, be made solely on the basis of the information contained in the prospectus. Thus, an investor is advised to read the entire prospectus.

Forward-looking statements

This press release may contain forward-looking information that reflects the Company's current views on future events and financial and operational development. Words such as "intend", "estimate", "expect", "may", "plan", "estimate" and other expressions that imply indications or predictions of future developments or trends, and which are not based on historical facts, constitute forward-looking information. By their nature, forward-looking statements involve both known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking information is not a guarantee of future performance or development and actual results may differ materially from those expressed in forward-looking statements. The information, opinions and forward-looking statements expressed or implied herein speak only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or Nasdaq Stockholm's rule book for issuers.

For further information, please contact:

Philip Siberg, CEO of Senszime AB

Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senszime.com

Slavoljub Grujicic, CFO

Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senszime.com

About Senszime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senszime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpirom® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX: SNZZF). More information is available at senszime.com.

Attachments

[Senzime publishes prospectus relating to the directed share issue](#)